

## Independent Auditor's Report

To

The Members of

**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**

**(previously known as VIHAAN MEDICARE PRIVATE LIMITED)**

**Report on Audit of Standalone Financial Statements**

### Opinion

We have audited the accompanying Standalone financial statements of **GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED** which comprise the Balance Sheet as at March 31, 2023 & statement of cash flows for the year then ended and notes to the financial statements, for the year then ended, and a summary of significant accounting policies and other explanatory information.

### Auditor's Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **31/03/2023**, and its **Profit** for the year ended on that date.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Other Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises Board's Report, Report on Corporate governance and Business Responsibility report but does not include the consolidated financial statement, standalone financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.





In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually





or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or



when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

1. This report doesn't include a statement on the matters specified in paragraph 3 and 4 of the Companies (Auditor's Report) Order, 2020, issued by the Central Government of India, in terms of sub section 11 of section 143 of the companies Act, 2013 since in Our opinion and according to the information and explanation given to us, the said order is not applicable to the company.
2. As required by section 143 (3) of the Act, we report that:
  - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) the Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - d) in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e) On the basis of written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) Since the Company is incorporated on 20/12/2019. There is no previous year audited financial statements which was less than Rs. 50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017.





g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and



c) Based on such audit procedures, we consider reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under a) and b) above, contain any material mis-statement.

v. Company has not declared or paid any dividend during the year.

For Vipul Shah & Co  
Chartered Accountants  
FRN :115087W

CA Vipul Shah  
Proprietor

M. No. 049035

UDIN : 23049035BGTE0Y3826

Date: 25 SEP 2023



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

(CIN : U85300GJ2019PTC111559)

**BALANCE SHEET AS AT 31st MARCH, 2023**

Particular	Note no.	As At 31st March, 2023	As At 31st March, 2022
<b>(I) EQUITY AND LIABILITIES</b>			
<b>(1) Shareholders' funds</b>			
(a) Share capital	2	20.00000	20.00000
(b) Reserves & Surplus	3	17.46654	18.08850
<b>(2) Current liabilities</b>			
(a) Trade Payables	4	346.75324	346.72324
(b) Other Current Liability	5	-	0.02796
(c) Short - Term Provisions	6	2.94000	8.38079
<b>Total Rs.</b>		<b>387.15978</b>	<b>393.22049</b>
<b>(II) ASSETS</b>			
<b>(1) Non-current assets</b>			
(a) Fixed assets			
(i) Property, Plant & Equipments	7	267.18155	267.18155
(ii) Intangible Assets		-	-
(b) Deferred Tax Asset		4.03640	4.03640
(c) Other Non cureent Assets	8	0.59472	0.59472
<b>(2) Current assets</b>			
(a) Trade Receivables	9	114.99227	116.06507
(a) Cash and cash equivalents	10	0.35484	0.33754
(b) Short term loans & Advances	11	-	5.00521
<b>Total Rs.</b>		<b>387.15978</b>	<b>393.22049</b>

**Notes forming Part of Accounts**

As per report of our even date Attached

**For Vipul Shah &co.**

**Charatered Accountant**

**For Gujarat Kidney and Superspciality Pvt. Ltd.**

CA. Vipul Shah

Proprietor

M No. 049035

FRN No. 115087W

UDIN: 23049035BGTE0Y3826

Anitaben Y Bharpoda, Bhartiben P Bharpoda

Director

Director

DIN:08644747

DIN: 08644746

Vadodara

Date: 12 / 5 / SEP 2023

**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)  
(CIN : U85300GJ2019PTC111559)  
**PROFIT & LOSS STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023**

(Rs. in Lakhs)

Particulars	Note No.	For the Year Ended 31st March, 2023	For the Year Ended 31st March, 2022
<b>Income:-</b>			
Revenue from operations		-	78.60372
Other Income	12	0.00990	-
<b>Total Income</b>		<b>0.00990</b>	<b>78.60372</b>
<b>Expenses:-</b>			
Employee benefits expense	13	-	4.80000
Other expenses	14	0.63186	2.93195
Depreciation and amortisation expense	7	-	57.40054
<b>Total Expenses</b>		<b>0.63186</b>	<b>65.13249</b>
<b>Profit Before Tax</b>		<b>-0.62196</b>	<b>13.47123</b>
<b>Less :</b>			
<b>Tax Expenses</b>			
Current Tax		-	5.49079
Deferred Tax		-	-1.86727
<b>Net Profit after Tax</b>		<b>-0.62196</b>	<b>9.84771</b>
Basic EPS		-0.31	4.92

1

Notes on Account  
Significant Accounting Policies  
As per Report of Even Date  
For Vipul Shah & Co.,  
Chartered Accountant

For Gujarat Kidney and Superspciality Pvt. Ltd.

CA Vipul Shah  
Proprietor  
M No. 049035  
FRN No. 115087W



U.DIN: 23049035 BGTcoy3826.

Anitaben Y Bharpoda  
Director  
DIN:08644747



Bhartiben P Bharpoda  
Director  
DIN: 08644746

VADODARA  
Date : 2 / 5 / SEP 2023



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)  
(CIN : U85300GJ2019PTC111559)  
Cash Flow Statement for the Year ended on 31st March, 2023

(Rs. In Lakhs)

PARTICULARS	For the Year Ended 31st March, 2023	For the Year Ended 31st March, 2022
<b>Cash From Operating Activities</b>		
Net Income before tax	-0.62196	13.47123
Interest Expenses	-	-
Add : Depreciation & Amortization	-	57.40054
<b>Operating Profit before Working Capital Changes</b>	<b>(0.62196)</b>	<b>70.87177</b>
<b>Add:-Change in Working Capital</b>		
(Increase)/Decrease in Other Receivables	6.07801	-67.35121
Increase/(Decrease) in Trade & Other Payable	-5.43875	0.33550
<b>Cash Generated from Operations</b>	<b>0.63926</b>	<b>(67.01571)</b>
<b>Less:-Tax Expenses</b>	<b>-</b>	<b>3.62352</b>
<b>Net Cash From Operating Activities(A)</b>	<b>0.01730</b>	<b>0.23254</b>
<b>Cash From Financing Activities</b>		
Interest Expenses	NIL	NIL
<b>Net Cash From Financing Activities(B)</b>	<b>-</b>	<b>-</b>
<b>Cash From Investing Activities</b>		
Equity share capital	-	-
Purchase of Fixed Asset	-	-
<b>Net Cash From Investing Activities( C )</b>	<b>-</b>	<b>-</b>
<b>Net Increase/( Decrease) in Cash or Cash Equivalents(A+B+C)</b>	<b>0.01730</b>	<b>0.23254</b>
Cash and Cash Equivalents at the beginning of the year	0.33754	0.10500
Cash and Cash Equivalents at the end of the year	0.35484	0.33754
	<b>(0.01730)</b>	<b>(0.23254)</b>

**Notes on Account**

**Significant Accounting Policies**

**As per Report of Even Date**

**For Vipul Shah & Co.**

**Charatered Accountant**

CA. Vipul Shah

Proprietor

M No. 049035

FRN No. 115087W



or Gujarat Kidney and Superspeciality Pvt. Ltd.

Anitaben Y Bharpoda, Bharuben P Bharpoda  
Director Director  
DIN:08644747 DIN: 08644746

DATE:- 25 SEP 2023  
VADODARA

**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
**(previously known as VIHAAN MEDICARE PRIVATE LIMITED)**  
**(CIN : U85300GJ2019PTC111559)**

**ACCOUNTING YEAR:- 2022-23**

**Note – 1:-**

**NOTES FORMING PART OF ACCOUNTS:**

**SIGNIFICANT ACCOUNTING POLICIES:**

**1. Nature of Business**

M/s GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED incorporated on December 20, 2019 having CIN : U85300GJ2019PTC111559.

M/s GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED is running a Multi Speciality Hospitals.

The company is compiling all the business & trade practice, and all applicable rule, as notified by appropriate authority, time to time.

**2. Basis of Preparation of Financial Statement:**

The financial Statements of the company has been prepared in accordance with the fundamental accounting assumption of Going concern, Consistency and Accrual Basis of accounting in accordance with the provisions of the companies act, 2013

The company is classified as Small and Medium sized company (SMC) as defined in General Instructions in respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the company has complied with the Accounting Standards as specified under section 133 of the companies Act 2013, applicable to a Small and Medium Sized Company

The company follows the mercantile system of Accounting and recognizes income & expenditure on accrual basis unless specifically stated otherwise.

There is no change in the accounting polices followed by the assessee vis-à-vis the previous year. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.





### 3. Use of Estimates :

The preparation of financial statements in conformity with the Generally Accepted Accounting Principles requires managements to make estimates and assumptions that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of income and expenses during the reporting period. Although these estimates are made on reasonable and prudent basis based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

Difference between the actual results and estimates (if any) will be recognized in the period in which the results are known/ materialized.

### 4. Property, Plant & Equipment :

Property, Plant & Equipment and Intangible assets are stated at Historical cost less net of depreciation .The cost of assets includes purchase price and any cost directly attribute to bringing the assets in working condition for its intended use .Assets retired from active use (If Any) are carried at lower of book value and estimated net realizable value. Advances (If Any),paid towards the acquisition of property, plant and equipment outstanding at each Balance Sheet date is classified as capital advances under other non-current assets and the cost of assets not ready to use before such date are disclosed under 'Capital work-in-progress'.

Subsequent expenditures relating to property, plant and equipment are capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the standalone Statement of Profit and Loss when incurred.

The cost and related accumulated depreciation are eliminated from the financial statements upon sale or retirement of the asset and the resultant gains or losses are recognized in the Consolidated Statement of Profit and Loss.

During the Financial year ended 31<sup>st</sup> March,2023, the company acknowledges that the Versius Surgical Robotic System was not put to operational use. The non utilization is attributed to combination of reasons viz: financial dispute with supplier of Versius Surgical Robotic System, its maintenance & operational efficiencies.

As a result of the non utilization, the company has assessed the carrying amount of the Versius Surgical Robotic System for any impairment in accordance with the applicable accounting standards. The assessment indicates that no impairment loss is deemed necessary as the recoverable amount exceeds the carrying value.

The management believes that the temporary non use of the Versius Surgical Robotic System does not adversely affect its long term value or future operational capabilities. The Company remains committed to optimizing the use of its assets in the upcoming periods.

The disclosure is made in accordance with the requirement of The Companies Act,2013 & Accounting standards to provide transparency regarding the utilization status of Significant asset.





5. **Depreciation :**

Systematic Allocation of Depreciation on Property, Plant & equipment has been provided over useful life in the manner prescribed under part C of the Schedule II of the Companies Act, 2013.

Depreciation methods, useful lives and residual values are reviewed periodically, including at each financial year end.

Please refer para 4 above for use of Versius Surgical Robotic System.

6. **Provision and Contingent Liabilities :**

The company recognizes a provision when there is a present obligation as a result of past event that requires an outflow of resources and a reliable estimate can be made of the amount of the obligation.

Contingent liabilities (If Any) are disclosed after careful evaluation by the management of facts and legal aspects of the matter involved.

Contingent Asset are neither recognized nor disclosed in the financial statements.

7. **Accounting for Retirement Benefits**

**Provident Fund - Defined Contribution Plan:**

As the provisions of The Employees' Provident Fund and Miscellaneous Provisions Act & Employees State Insurance Act are not applicable to the company, the same are not accounted for.

**Gratuity - Defined Benefit Plans:**

Liability in respect of present liability or future payment of gratuity will be ascertained and provided in the accounts as & when applicable. Gratuity payments to the employees are to be accounted on Cash Basis.

**Short term Benefits:**

Short term benefits are recognized as an expense at the undiscounted amount in profit & loss account of the year in which related services are rendered.

8. **Earning per Share:**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

9. **Statutory Dues:**

As per the information & explanation given to us the company is regular in departing undisputed dues.

Balance shown in GST Input and GST Output Ledgers under the head Loans & advances may not necessarily reconcile with the GSTR3B, GSTR1 and GSTR-2A Returns filed by the Company and Suppliers of the company. The same are subject to reconciliation and rectification, wherever necessary and shall be finalized at the time of filing of Annual Return by the Company. The Current GST Input Credit / GST output Liabilities are stated





based on the books of accounts maintained by the Company. Financial Impact on account of such reconciliation / rectification shall be quantified and accounted for only at the time of finalization of the GST Annual Return GSTR-9 of the Company

#### **10. Revenue Recognition :**

Revenue is recognized only when it can be reliably measured & it is reasonably certain for ultimate collection.

All material known liabilities are provided for on the basis of available information & supporting documents. Whenever external evidences for expenses are not available, authorization & certification of management is placed on record.

All other income and expenses are recognized on accrual basis.

#### **11. Income Taxes**

Tax expenses includes current income tax and deferred income tax.

Current period tax is measured and accounted at the amount expected to be paid to Indian tax authorities in accordance with the provisions of income tax act, 1961.

Deferred income tax reflects the effects of Timing Differences' between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred income tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date and are expected to apply to taxable income in the years in which those temporary

Differences are expected to be recovered or settled.

The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. A deferred income tax asset is recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilized.

Company has opted to forgo the mat credit under section 115BAA of the income Tax Act, 1961.

#### **B. NOTES TO BALANCE SHEET AND PROFIT AND LOSS ACCOUNT:**

1. Estimated amount of contracts remaining to be executed on capital account and not provided for Rs. NIL
2. Contingent Liabilities : NIL
3. Additional information required to be disclosed pursuant to clause 3 & 4 of the part II of Schedule III of the Companies Act, 2013 are not applicable to the company.



4. Earnings Per Share (EPS) :

The numerators and denominators used to calculate Basic Earnings per Share:

Particulars	(Rs. In Lakhs)	
	Current Year	Previous Year
Profit available to Equity Shareholders After Tax / Deferred Tax	-0.62196	9.84771
Weighted Average No. of Equity Shares Outstanding	200000	200000
Nominal Value of Equity Shares	10	10
Basic Earnings Per Share	-0.31	4.92

5. Remuneration to / Transaction With Directors:

(Rs. In Lakhs)

Particulars	Current Year	Previous Year
Dr. Pragnesh Bharpoda	0.00000	2.40000
Dr. Yashwant Bharpoda	0.00000	0.00000

6. Auditors' Remuneration:

(Rs. In Lakhs)

Particulars	Current Year	Previous Year
Audit & Taxation Matter Fees	0.30000	0.29500
<b>Total</b>	<b>0.30000</b>	<b>0.29500</b>

7. Deferred Tax Asset comprise of the following:

In view of AS-22 issued by ICAI, the Company has started accounting for Deferred Taxes. The net Deferred Tax Assets as on March 31, 2022 amounting to Rs. 4,03,640/- has been arrived at as follows:

Please refer para 4 for non use of Versius Surgical Robotic System. There is no operating income in the company during FY 2022-23. Depreciation as per The Companies Act, 2013 and Income Tax Act, 1961 is not charged. Therefore, Deferred Tax Income or Expense is not recognized in FY 2022-23.





(Rs. In Lakhs)

Particulars	Amount (Rs.)	
	2022-23	2021-22
<b>Deferred Tax Assets (Current year)</b>		
WDV as per IT		283.22000
WDV as per Co Act		267.18155
WDV Differences		6.03845
<b>Deferred Tax Asset @ 25.167%</b>	<b>0.00000</b>	<b>1.86727</b>

The tax impact for the above purpose has been arrived by applying a tax rate of 25.167% being the prevailing tax rate for Indian companies under the Income Tax Act, 1961.

8. Related Party Disclosures:

1. Nature of Relationship:

A) Key Management Personnel:	1) Anitaben Y Bharpoda 2) Bhartiben P Bharpoda 3) Pragnesh Y Bharpoda 4) Yashwantsingh Bharpoda
B) Relatives of Key Management Personnel:	NIL
C) Entities over which KMP and their Relatives are able to exercise significant influence or control	Gujarat Kidney and Superspeciality Hospital

2. Transactions with Related Parties (Annexure – A)

(Rs. In Lakhs)

Nature of Transactions	Current Year
Purchase of Goods / Services	NIL
Sale of Goods/ Services	NIL
Purchase of Fixed Assets	NIL
<b>Expenditure incurred :</b>	
Remuneration to Director	NIL
<b>Finance &amp; Investments :</b>	
1) Outstanding Receivables	114.99227
2) Outstanding Payable	0.00000



10. In the opinion of Board, the value of realization of Current Assets, Loans & Advances in ordinary course of business will not be less than the amount at which they are stated in the Balance Sheet.
11. The company is in the process of gathering the information from its suppliers, to know whether they are covered by the Micro Small and Medium Enterprises Development Act, 2006 (MSMEDA, 2006) and whether they have filed Memorandum under Section 8 of the said Act to the respective authorities. In the absence of any response from the suppliers, the company is not in a position to comply with the disclosure requirements of MSMED Act, 2006.
12. The company is a Small and Medium sized company (SMC) as defined in General Instructions in respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.
13. The Balances of Other Liabilities and Advances recoverable are subject to confirmations.

**FOR VIPUL SHAH & CO  
CHARTERED ACCOUNTANTS**

*V. Shah*  
**CA. VIPUL SHAH**  
**M No. 049035**  
**FRN NO. 115087W**  
**Proprietor**

**Date :- 25 SEP 2023**

**Place:-VADODARA**



**FOR & ON BEHALF OF BOARD  
GUJARAT KIDNEY AND SUPERSPECIALITY  
PRIVATE LIMITED**

*Anita*  
**Anitaben Bharpoda**  
**Director**  
**DIN : 08644747**

*Bharti*  
**Bhartiben P Bharpoda**  
**Director**  
**DIN : 08644746**





9 Additional Regulatory Information:

(i)	Title deeds of Immovable Property not held in name of the Company	There is no immovable property held in the name of company during FY 2022-23 hence this clause is not applicable.					
(ii)	Capital-Work-in Progress (CWIP)	There is no CWIP as on 31/03/2023					
(iii)	Intangible assets under development	There is no any Intangible assets under development hence this clause is not applicable.					
(iv)	Details of Benami Property held	There is no proceeding has been initiated or pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder hence this clause is not applicable.					
(v)	Willful Defaulter	Any bank or financial Institution or other lender is not declared company as Willful Defaulter in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India till date hence this clause is not applicable to the said company.					
(vi)	Relationship with Struck off Companies	There is no relationship with struck off companies. Hence, this clause is not applicable.					
(vii)	Registration of charges or satisfaction with Registrar of Companies	No charges exists as no debt of the company hence this clause is not applicable.					
(viii)	Compliance with number of layers of companies	This clause is not applicable to the said company being subsidiary Company					
(ix)	Ratio Calculations	Refer following table for details					
(x)	Compliance with approved Scheme(s) of Arrangements	This clause is not applicable.					
(xi)	Utilisation of Borrowed funds and share premium	No such advanced or loaned or invested funds by company					
<b>Ratio Analysis</b>							
<b>Ratios</b>		<b>Numerator</b>	<b>Denominator</b>	<b>As at March 31,2023</b>	<b>As at March 31,2022</b>	<b>Variance (%)</b>	<b>Explanation for any change in the ratio by more than 25% as compared to the preceeding year</b>
(a)	Current Ratio	Current Assets	Current Liabilities	0.33	0.34	-4%	
(b)	Debt-Equity Ratio	Total Debt	Shareholders' equity	-	-	0%	
(c)	Debt Service Coverage Ratio (DSCR)	Earning available for debt service	Debt service	-	-	0%	
(d)	Return on Equity ratio (ROE)	Net profit after taxes less preference dividend (if any)	Average Shareholders' equity	-0.03	0.67	-105%	Loss during the year
(e)	Inventory Turnover Ratio	Cost of goods sold or sales	Average Inventory	-	-	0%	
(f)	Trade Receivables Turnover Ratio	Net credit sales	Average trade receivables	-	0.92	-100%	No sales made during the year
(g)	Trade Payables Turnover Ratio	Net credit purchases	Average trade payables	-	-	0%	
(h)	Net Capital Turnover Ratio	Net sales	Average working capital	-	-0.34	-100%	No sales made during the year
(i)	Net Profit Ratio	Net profit after taxes	Net sales	-	0.17	-100%	Loss during the year and no sales made during the year
(j)	Return on Capital Employed	Earning before interest and taxes	Capital employed	-0.02	0.35	-105%	Loss during the year
(k)	Return on Investment	Income from Investments	Cost of investment	-0.00	0.03	-105%	Loss during the year



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

**Note -2. SHARE CAPITAL**

(Rs. in Lakhs)

Particulars	Balance as at March 31, 2023		Balance as at March 31, 2022	
	Number of shares	Rs.	Number of shares	Rs.
(a) Authorised				
250000 Equity Shares	250000	25.00000	250000	25.00000
of Rs. 10 each fully paid up				
(b) Issued, Subscribed and Paid up				
200000 Equity Shares	2,00,000	20.00000	200000	20.00000
at Rs. 10 each fully paid up				
<b>Total</b>	<b>2,00,000</b>	<b>20.00000</b>	<b>2,00,000</b>	<b>20.00000</b>

**List of Shareholders holding more than 5% share capital**

Name of Shareholders	No. of Shares	%	Value/Share	Total Value
Anitaben Y Bharpoda	50,000	25%	10	5.00000
Bhartiben P Bharpoda	50,000	25%	10	5.00000
Pragnesh Y Bharpoda	50,000	25%	10	5.00000
Yashwantsingh Bharpoda	50,000	25%	10	5.00000
<b>TOTAL</b>	<b>2,00,000</b>	<b>100%</b>		<b>20.00000</b>

**NOTE 2A. SHARES HELD BY PROMOTORS**

As at March 31, 2023				
Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Anitaben Y Bharpoda	50,000	25.00%	-
2	Bhartiben P Bharpoda	50,000	25.00%	-
3	Pragnesh Y Bharpoda	50,000	25.00%	-
4	Yashwantsingh Bharpoda	50,000	25.00%	-

As at March 31, 2022				
Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Anitaben Y Bharpoda	50,000	25.00%	-
2	Bhartiben P Bharpoda	50,000	25.00%	-
3	Pragnesh Y Bharpoda	50,000	25.00%	-
4	Yashwantsingh Bharpoda	50,000	25.00%	-

**NOTE- 2B. STATEMENTS OF CHANGES IN EQUITY**

As at March 31, 2023				
Balance as at April 1, 2022	Changes in Equity Share Capital due to prior period errors	Restated Balance as at April 1, 2022	Changes in Equity Share Capital during the current year	Balance as at March 31, 2023
20.00000	0	20.00000	0	20.00000

As at March 31, 2022				
Balance as at April 1, 2021	Changes in Equity Share Capital due to prior period errors	Restated Balance as at April 1, 2021	Changes in Equity Share Capital during the previous year	Balance as at March 31, 2022
20.00000	0	0	0	20.00000

For Gujarat Kidney and Superspeciality Pvt. Ltd.

Anita  
Anitaben Y Bharpoda  
Director  
DIN: 08644747



Bharts  
Bhartiben P Bharpoda  
Director  
DIN: 08644746





**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

	(Rs. In Lakhs)	
	March 31, 2023	March 31, 2022
	Rs.	Rs.
<b>Note No. - 3</b>		
<b>Reserves &amp; Surplus</b>		

**Surplus / (Deficit) in Statement of Profit and Loss**

Opening Balance B/F	18.08850	8.24079
Add : Profit for the Year	-0.62196	9.84771

<b>Total Rs.</b>	<b>17.46654</b>	<b>18.08850</b>
------------------	-----------------	-----------------

	March 31, 2023	March 31, 2022
	Rs.	Rs.
<b>Note No. - 4</b>		

**Trade Payables**

CMR Surgical India Pvt Ltd	342.29824	342.29824
Dr. Yashwant Bharpoda - Director	2.00000	2.00000
VIPUL SHAH & CO	0.05500	0.02500
Litul Kansara	2.40000	2.40000

<b>Total Rs.</b>	<b>346.75324</b>	<b>346.72324</b>
------------------	------------------	------------------

**Balance as at March 31, 2023**

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	0.05500	4.40000	342.29824	-	346.75324
Dispute dues-MSME	0	0	0	0	0
Dispute dues	0	0	0	0	0
Others	0	0	0	0	0
<b>Total</b>	<b>0.05500</b>	<b>4.40000</b>	<b>342.29824</b>	<b>-</b>	<b>346.75324</b>

**Balance as at March 31, 2022**

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	4.42500	342.29824	0	0	346.72324
Dispute dues-MSME	-	0	0	0	0
Dispute dues	-	0	0	0	0
Others	-	0	0	0	0
<b>Total</b>	<b>4.42500</b>	<b>342.29824</b>	<b>-</b>	<b>-</b>	<b>346.72324</b>

For Gujarat Kidney and Superspeciality Pvt. Ltd.

Anita  
Anitaben Y Bharpoda  
Director  
DIN: 08644747

Bharti  
Bhartiben P Bharpoda  
Director  
DIN: 08644746



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

	(Rs. In Lakhs)	
	March 31, 2023	March 31, 2022
<u>Note No. - 5</u>		
Other Current Liabilities	Rs.	Rs.
TDS Payable	-	0.02796
<b>Total Rs.</b>	<b>-</b>	<b>0.02796</b>

	March 31, 2023	March 31, 2022
<u>Note No. - 6</u>		
Short Term Provisions	Rs.	Rs.
Income Tax Provision	-	5.49079
Professional Charges Payable	0.30000	0.25000
Salary Payable	2.64000	2.64000
<b>Total Rs.</b>	<b>2.94000</b>	<b>8.38079</b>

For Gujarat Kidney and Superspeciality Pvt. Ltd.

*Anita*  
**Anitaben Y Bharpoda**  
Director  
DIN:08644747



*Bharti*  
**Bhartiben P Bharpoda**  
Director  
DIN: 08644746





**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

**Note No. - 7**

**Property, Plant & Equipments and Intangible Asset & Depreciation Statement as per Companies Act, 2013**

Particulars	GROSS BLOCK			DEPRECIATION BLOCK			NET BLOCK	
	As at 01/04/2022	Addition	Adjustments	As at 31/03/2023	As at 01/04/2022	Addition	As at 31/03/2022	As at 31/03/2023
Versius Surgical Robotic System	392.00000	0	0	392.00000	124.81845	0	267.18155	267.18155
<b>Total Rs.</b>	<b>392.00000</b>	<b>0.00000</b>	<b>0.00000</b>	<b>392.00000</b>	<b>124.81845</b>	<b>0.00000</b>	<b>267.18155</b>	<b>267.18155</b>
<b>Previous Year Rs.</b>	<b>392.00000</b>	<b>0.00000</b>	<b>Nil</b>	<b>392.00000</b>	<b>Nil</b>	<b>57.40054</b>	<b>324.58209</b>	<b>267.18155</b>

For Gujarat Kidney and Superspeciality Pvt. Ltd.

*Anita*  
Anitaben Y. Bhatnagar  
Director  
DIN: 08644747

*Bhaskar*

Bhaskar P. Bharpoda  
Director  
DIN: 08644746



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

Note No. - 8 Other Non Current Assets	(Rs. In Lakhs)	
	March 31, 2023 Rs.	March 31, 2022 Rs.
Misc. Expenditure		
Preliminary Expense	0.59472	0.79296
Less : 1/5th written off	0.00000	0.19824
<b>Total Rs.</b>	<b>0.59472</b>	<b>0.59472</b>

Note No. - 9 Trade Receivables	(Rs. In Lakhs)	
	March 31, 2023 Rs.	March 31, 2022 Rs.
Gujarat Kidney Superspeciality Hospital	114.99227	116.06507
<b>Total Rs.</b>	<b>114.99227</b>	<b>116.06507</b>

Balance as at March 31, 2023

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables-Considered Goods	-	-	114.99227	-	-	114.99227
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

Balance as at March 31, 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables-Considered Goods	-	-	116.06507	-	-	116.06507
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

For Gujarat Kidney and Superspeciality Pvt. Ltd.

Anita  
Anitaben Y Bharpoda  
Director  
DIN: 08644747



Bhartiben P Bharpoda  
Director  
DIN: 08644746





**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

	(Rs. In Lakhs)	
	March 31, 2023	March 31, 2022
<u>Note No. - 10</u>		
<b>Cash &amp; Cash Equivalents</b>	<b>Rs.</b>	<b>Rs.</b>
HDFC Bank Ltd	0.35484	0.33754
<b>Total Rs.</b>	<b>0.35484</b>	<b>0.33754</b>

	March 31, 2023	March 31, 2022
<u>Note No. - 11</u>		
<b>Short Term Loans &amp; Advances</b>		
<b>Loans &amp; Advances</b>		
(Unsecured, Considered good, Recoverable in cash or kind or value to be received)		
Advance Tax	0.00000	5.00000
TCS Receivable	0.00000	0.00521
<b>Total Rs.</b>	<b>0.00000</b>	<b>5.00521</b>

For Gujarat Kidney and Superspeciality Pvt. Ltd.

*Anita*  
**Anitaben Y Bharpoda**  
Director  
DIN:08644747



*Bharti*  
**Bhartiben P Bharpoda**  
Director  
DIN: 08644746



**GUJARAT KIDNEY AND SUPERSPECIALITY PRIVATE LIMITED**  
(previously known as VIHAAN MEDICARE PRIVATE LIMITED)

Notes on Financial Statement for the Year ended 31st March, 2023

(Rs. In Lakhs)

<u>Note No. - 12</u>	March 31, 2023	March 31, 2022
Other Income	Rs.	Rs.
Income tax Refund	0.00990	0.00000
<b>Total Rs.</b>	<b>0.00990</b>	<b>0.00000</b>

<u>Note No. - 13</u>	March 31, 2023	March 31, 2022
Employee Benefits expense	Rs.	Rs.
Director Remuneration	0.00000	2.40000
Salary Expense	0.00000	2.40000
<b>Total Rs.</b>	<b>0.00000</b>	<b>4.80000</b>

<u>Note No. - 14</u>	March 31, 2023	March 31, 2022
Other Expenses	Rs.	Rs.
Advertisement Expense	0.00000	1.51392
Audit Fees	0.40400	0.29500
Interest on TDS	0.00084	0.02480
Interest on Income tax	0.22702	0.89999
Preliminary Expense W/off	0.00000	0.19824
<b>Total Rs.</b>	<b>0.63186</b>	<b>2.93195</b>

For Gujarat Kidney and Superspeciality Pvt. Ltd.



  
**Anitaben Y Bharpoda** **Bhartiben P Bharpoda**  
**Director** **Director**  
**DIN:08644747** **DIN: 08644746**





Annexure:-A - Related party Transactions						
Sr. No.	Name	Relation	Dire. Remu.	Medical Receipt	Outstanding Receivable	Outstanding Payable
1	Gujarat Kidney and Superspeciality Hospital	Proprietary Firm of Director	-	-	1,14,99,227	-
	<b>TOTAL</b>		-	-	1,14,99,227	-

For Gujarat Kidney and Superspeciality Pvt. Ltd.



Anita  
Anitaben Bharpoda  
Director  
DIN : 08644747

Bhariben Bharpoda  
Director  
DIN : 08644746

Gujarat Kidney and Superspeciality Pvt. Ltd.  
VADODARA